Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

Sep 16, 2020
|
Madeleine Johnson
Premium

This story has been updated to include additional commentary from test developers.

NEW YORK – The US Food and Drug Administration on Tuesday published the first results of a limit of detection comparison of Emergency Use Authorized molecular diagnostic tests for SARS-CoV-2.

Reported as nucleic acid amplification test-detectable units (NDU) per milliliter, the limits of detection for the first batch of 55 tests reported differed by 10,000-fold.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Vaccine Supply Chain Hacker Warning

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

Illinois Cuts Forensic Testing Backlog

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

Lying Plea

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

Science Studies on Nonalcoholic Fatty Liver Disease Expression Signatures, Ties Between Gut Microbiome and Major Depression

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.

What's Popular?

In PCR

  1. FDA Authorizes Use of Pooled Samples With CDC Coronavirus Test

  2. Point-of-Care Roche Liat SARS-CoV-2 Test Shows High Sensitivity in Multisite Trial

    Premium

  3. DnaNudge Deploys Direct-to-Consumer Service for PCR-Based Pool Testing of SARS-CoV-2

    Premium

  4. Cepheid, Roche Coronavirus Tests Get FDA Emergency Use Authorization

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.